Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)
NCT07220252Phase 3Recruiting
- Sponsor
- TG Therapeutics, Inc.
- Start
- Jul 2026
- Primary completion
- Jan 2030
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of ublituximab in multiple sclerosis (MS), sponsored by TG Therapeutics, Inc.. Started Jul 2026; status: recruiting.
02
Drugs
ublituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07220252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07220252.